Biotech Startups

Perosphere is a medical technology company developing point-of-care coagulation diagnostics, including a pharmacodynamic test that provides a global view of a patient's coagulation status. Its lead product is CE Marked in the European Union but not FDA cleared in the United States.

2 investors

PFx Biotech develops alternative protein products aimed at meeting high nutritional standards and offering health-promoting properties. The company operates in the alternative protein and biotech space.

2 investors

Pharaoh Neuro is a neurotechnology company focused on protecting and restoring brain health, with an emphasis on the fluids surrounding the brain such as cerebrospinal fluid. It develops devices and technology in the neurology and brain health category.

2 investors

PharmAbcine is a biotech company developing therapeutic antibodies, with a focus on immuno-oncology and antibody-based cancer treatments.

2 investors

PharmaJet develops needle-free injection systems for delivering vaccines and therapeutics, used across a range of therapeutic areas including infectious disease prevention and cancer treatment. Its reusable devices serve pharmaceutical partners and healthcare providers as an alternative to traditional needle-based delivery.

2 investors

PharOS develops and markets generic and value-added pharmaceutical products for distribution to more than 115 countries. The company employs scientists, biologists, chemists, and pharmacists focused on drug development with emphasis on customer service and product lifecycle extension.

2 investors

Phase Genomics develops long-range genome sequencing technology based on proximity ligation, along with computational tools, for scientists studying cancer, inherited diseases, microbiomes, and biodiversity. It serves academic and research institutions and biopharmaceutical firms across life sciences, medicine, and agriculture.

2 investors

PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.

2 investors

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute. The company focuses on translating scientific discoveries into clinical therapies for patients.

2 investors

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair. Its therapeutics address neurodegenerative and demyelinating disorders such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.

2 investors

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

2 investors

PhiTech is a TechBio company that develops AI-powered multi-omics diagnostic platforms for rare diseases and hereditary cancers. The company serves hospitals, laboratories, and pharmaceutical companies seeking to improve diagnosis and treatment decisions for complex genetic conditions.

2 investors

Phlox Therapeutics develops RNA-based precision genetic medicines and gene therapies to treat and potentially cure rare genetic heart diseases such as cardiomyopathies and laminopathies. The company targets the underlying causes of genetic cardiac dysfunction for patients underserved by current standard of care.

2 investors

Phycin develops engineered growth factors designed for higher stability and performance, including a thermostable recombinant basic fibroblast growth factor (bFGF) that remains active for 21+ days at 37°C. Its products target researchers and clinicians working in regenerative medicine, cell culture, and related life science applications.

2 investors

Phyco Bloom uses synthetic biology to engineer algae that capture carbon dioxide and convert it into oil for use as a sustainable fuel or plastic feedstock. The company targets applications such as aviation, shipping, and materials production.

2 investors

Phycus Bio produces Purolic Acid™, a biobased glycolic acid made through fermentation using renewable, FSC-certified wood feedstock for cosmetic, personal care, adhesive, coating, and polymer applications. The company aims to replace petrochemical-derived glycolic acid with a sustainable alternative that reduces greenhouse gas emissions and eliminates formaldehyde impurities.

2 investors

Phylos develops elite, phenotypically-stable, fully-feminized F1 hybrid cannabis seeds designed to give growers uniform, high-THC plants with agronomic traits that reduce production costs. The company serves cannabis cultivators of all sizes as an alternative to clonal propagation.

2 investors

Pi Health develops software and AI tools to make clinical research more inclusive, efficient, and globally scalable by eliminating barriers in clinical trial recruitment and execution for pharmaceutical and biotech companies.

2 investors

Pictor Diagnostics develops a proteomics platform that enables researchers, diagnostics manufacturers, clinical labs, and veterinary clinics to perform multi-marker protein testing across diverse sample types. The platform combines an affordable instrument and assays that integrate into existing lab workflows without requiring specialized equipment or training.

2 investors

Pili manufactures biosourced and decarbonized industrial dyes and pigments for textiles, inks, polymers, paints, and coatings using hybrid fermentation and organic chemistry processes. The company aims to replace fossil fuel-derived colors with sustainable, high-performance alternatives, starting with indigo for the denim industry.

2 investors

Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.

2 investors

PinotBio is a biotechnology company developing novel anticancer treatments, including its PINOT-ADC antibody-drug conjugate platform and the PBX-001 drug candidate. It focuses on cancer therapy within the biotech and drug development industry.

2 investors

PipeBio provides a bioinformatics platform for drug discovery that enables scientists and bioinformaticians to analyze genomic and assay data. The platform combines sequence data management, machine learning tools, and visualization capabilities to accelerate therapeutic development for academia, biotech companies, and pharmaceutical firms.

2 investors

Pitri uses synthetic biology to engineer fungi that produce colorants intended as alternatives to petroleum-derived dyes. The pigments are aimed at manufacturers of cosmetics, packaging, and paints looking for non-toxic, bio-based options.

2 investors